Clinical Trial Update: Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating first-line durvalumab plus tremelimumab in Chinese patients with unresectable hepatocellular carcinoma is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (Imfinzi) (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: RECRUITING